Vanguard Group Inc Akebia Therapeutics, Inc. Transaction History

Vanguard Group Inc

  • $6.44 Trillion
  • Q3 2025

A detailed history of Vanguard Group Inc transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 15,547,508 shares of AKBA stock, worth $26.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
15,547,508
Previous 14,611,466 6.41%
Holding current value
$26.4 Million
Previous $53.2 Million 21.07%
% of portfolio
0.0%
Previous 0.0%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 07, 2025
BUY
$2.7 - $4.01 $2.53 Million - $3.75 Million
936,042 Added 6.41%
15,547,508 $42 Million
Q2 2025

Aug 11, 2025
BUY
$1.55 - $3.97 $2.98 Million - $7.64 Million
1,925,663 Added 15.18%
14,611,466 $53.2 Million
Q1 2025

May 09, 2025
BUY
$1.69 - $2.84 $3.04 Million - $5.12 Million
1,801,603 Added 16.55%
12,685,803 $24.4 Million
Q4 2024

Feb 11, 2025
BUY
$1.26 - $2.13 $1.03 Million - $1.73 Million
813,902 Added 8.08%
10,884,200 $20.2 Million
Q3 2024

Nov 13, 2024
BUY
$0.94 - $1.55 $746,392 - $1.23 Million
794,035 Added 8.56%
10,070,298 $13.3 Million
Q2 2024

Aug 13, 2024
BUY
$0.86 - $1.63 $903,250 - $1.71 Million
1,050,291 Added 12.77%
9,276,263 $9.46 Million
Q1 2024

May 10, 2024
BUY
$1.27 - $2.24 $785,495 - $1.39 Million
618,500 Added 8.13%
8,225,972 $15.1 Million
Q4 2023

Feb 14, 2024
BUY
$0.8 - $1.28 $68,924 - $110,278
86,155 Added 1.15%
7,607,472 $9.43 Million
Q3 2023

Nov 14, 2023
SELL
$0.87 - $1.84 $252,077 - $533,128
-289,744 Reduced 3.71%
7,521,317 $8.57 Million
Q2 2023

Aug 14, 2023
SELL
$0.51 - $1.43 $2.4 Million - $6.72 Million
-4,699,843 Reduced 37.57%
7,811,061 $7.19 Million
Q1 2023

May 15, 2023
BUY
$0.56 - $1.15 $712,339 - $1.46 Million
1,272,034 Added 11.32%
12,510,904 $7.01 Million
Q4 2022

Feb 10, 2023
SELL
$0.25 - $0.58 $485,998 - $1.13 Million
-1,943,995 Reduced 14.75%
11,238,870 $6.52 Million
Q3 2022

Nov 14, 2022
SELL
$0.3 - $0.46 $922,871 - $1.42 Million
-3,076,239 Reduced 18.92%
13,182,865 $4.17 Million
Q2 2022

Aug 12, 2022
BUY
$0.32 - $0.67 $593,957 - $1.24 Million
1,856,116 Added 12.89%
16,259,104 $5.74 Million
Q1 2022

May 13, 2022
BUY
$0.72 - $2.93 $840,469 - $3.42 Million
1,167,319 Added 8.82%
14,402,988 $10.3 Million
Q4 2021

Feb 14, 2022
BUY
$2.26 - $3.34 $1.86 Million - $2.75 Million
824,426 Added 6.64%
13,235,669 $29.9 Million
Q3 2021

Nov 12, 2021
BUY
$2.35 - $3.88 $600,481 - $991,433
255,524 Added 2.1%
12,411,243 $35.7 Million
Q2 2021

Aug 13, 2021
BUY
$2.83 - $4.2 $34.4 Million - $51.1 Million
12,155,719 New
12,155,719 $46.1 Million

Others Institutions Holding AKBA

# of Institutions
189
Shares Held
121M
Call Options Held
267K
Put Options Held
280K
View Full List

About Akebia Therapeutics, Inc.

AKBA Quotes by TradingView
  • Ticker AKBA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 183,848,992
  • Market Cap $313M
  • Description
  • Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...
More about AKBA
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email